KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Long-Term Deferred Tax (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Long-Term Deferred Tax for 11 consecutive years, with $1.6 billion as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Long-Term Deferred Tax fell 21.06% year-over-year to $1.6 billion, compared with a TTM value of $1.6 billion through Sep 2025, down 21.06%, and an annual FY2024 reading of $1.8 billion, down 0.72% over the prior year.
  • Long-Term Deferred Tax was $1.6 billion for Q3 2025 at Teva Pharmaceutical Industries, down from $1.8 billion in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $2.1 billion in Q3 2024 and bottomed at $596.0 million in Q4 2021.
  • Average Long-Term Deferred Tax over 5 years is $1.4 billion, with a median of $1.6 billion recorded in 2022.
  • The sharpest move saw Long-Term Deferred Tax soared 148.55% in 2022, then dropped 21.06% in 2025.
  • Year by year, Long-Term Deferred Tax stood at $596.0 million in 2021, then surged by 143.79% to $1.5 billion in 2022, then rose by 24.71% to $1.8 billion in 2023, then fell by 0.72% to $1.8 billion in 2024, then fell by 9.17% to $1.6 billion in 2025.
  • Business Quant data shows Long-Term Deferred Tax for TEVA at $1.6 billion in Q3 2025, $1.8 billion in Q2 2025, and $1.8 billion in Q1 2025.